School of Medicine and Health Sciences Poster Presentations
Rheumatological Disease from Cardiac Point of View: A Systematic Review
Poster Number
160
Document Type
Poster
Publication Date
3-2016
Abstract
Objectives
Rheumatic diseases are associated with an increased risks of premature cardiovascular mortality. The aim of our study was to conduct a systematic review of the literature regarding the cardiovascular involvement in various rheumatic diseases. Commonly used treatments for rheumatic disease and their cardiovascular side effects were studied as well.
Methods
Online databases (Pubmed and Medline) were searched from inception to January 2016. Search terms included: “systemic lupus erythematosus”, “rheumatoid arthritis”, “cardiovascular diseases”, “cardiovascular mortality”, “sudden cardiac death”, and “atherosclerosis”. Studies meeting the following criteria were included: (a) Articles are written in English language, (b) Reference to the cardiac involvement in rheumatic diseases, and (c) Articles where full text available.
Results
We identified 12,336 citations. After screening retrieved citations, 160 articles were included based on the predetermined criteria. Overall, pericarditis was considered the most common finding in rheumatic disease (50 %). In addition, myocarditis was more prevalent in Churg-Strauss syndrome (30%), Takayasu's disease (45%), and systemic sclerosis (25%), and coronary angiitis was more common in polyarteritis nodosa (40%), Takayasu's disease (40%), and Behcet disease (17%). Accelerated atherosclerosis has been increasingly reported especially due to chronic systemic inflammation associated with rheumatic disease. As expected, the cardiac side effects of systemic glucocorticoids are well documented and frequently seen in the management of rheumatic diseases (12%). Followed by epoprostenole (11%) and rituximab (11%).
Conclusions
Cardiovascular diseases are commonly encountered in rheumatic disease. The current systematic review was useful in describing the prevalence of cardiovascular involvement in each of the rheumatic disease. Close collaboration is needed between cardiologists and rheumatologists in managing this group of patients for overlapping conditions. Further research is needed to understand the impact of cardiovascular diseases on morbidity and mortality in rheumatic diseases.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Open Access
1
Rheumatological Disease from Cardiac Point of View: A Systematic Review
Objectives
Rheumatic diseases are associated with an increased risks of premature cardiovascular mortality. The aim of our study was to conduct a systematic review of the literature regarding the cardiovascular involvement in various rheumatic diseases. Commonly used treatments for rheumatic disease and their cardiovascular side effects were studied as well.
Methods
Online databases (Pubmed and Medline) were searched from inception to January 2016. Search terms included: “systemic lupus erythematosus”, “rheumatoid arthritis”, “cardiovascular diseases”, “cardiovascular mortality”, “sudden cardiac death”, and “atherosclerosis”. Studies meeting the following criteria were included: (a) Articles are written in English language, (b) Reference to the cardiac involvement in rheumatic diseases, and (c) Articles where full text available.
Results
We identified 12,336 citations. After screening retrieved citations, 160 articles were included based on the predetermined criteria. Overall, pericarditis was considered the most common finding in rheumatic disease (50 %). In addition, myocarditis was more prevalent in Churg-Strauss syndrome (30%), Takayasu's disease (45%), and systemic sclerosis (25%), and coronary angiitis was more common in polyarteritis nodosa (40%), Takayasu's disease (40%), and Behcet disease (17%). Accelerated atherosclerosis has been increasingly reported especially due to chronic systemic inflammation associated with rheumatic disease. As expected, the cardiac side effects of systemic glucocorticoids are well documented and frequently seen in the management of rheumatic diseases (12%). Followed by epoprostenole (11%) and rituximab (11%).
Conclusions
Cardiovascular diseases are commonly encountered in rheumatic disease. The current systematic review was useful in describing the prevalence of cardiovascular involvement in each of the rheumatic disease. Close collaboration is needed between cardiologists and rheumatologists in managing this group of patients for overlapping conditions. Further research is needed to understand the impact of cardiovascular diseases on morbidity and mortality in rheumatic diseases.
Comments
Presented at: GW Research Days 2016